An observational study in Chronic Iron Overload, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)
156 studies on the registry are indexed under Iron Overload; 6 are open to participants now.
This study's enrollment of 400 is above the median of 94 across 49 observational studies indexed under Iron Overload.
Browse Iron Overload studies →Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exjade (deferasirox) prescribers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Physicians will be required to meet all of the following inclusion criteria:
Exclusion Criteria:
Physicians meeting the following criterion will not be eligible to take the survey:
HCPs prescribing Exjade in the EU/EEA provided with Exjade Educational Materials
Other: Physician survey
Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
Mean percentage of correct responses related to knowledge of posology and biological monitoring recommendations as described in the Exjade EU Summary of Product Characteristics (SmPC)
The primary endpoint is a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information: * Administration and dosing of Exjade (deferasirox) FCT * Biological monitoring
Time frame: Through study completion, an average of 6 months.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.